Simplex Trading, LLC Cure Vac N.V. Transaction History

Simplex Trading, LLC

$2.98 Billion
Q2 2024

A detailed history of Simplex Trading, LLC transactions in Cure Vac N.V. stock. As of the latest transaction made, Simplex Trading, LLC holds 4,391 shares of CVAC stock, worth $13,173. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,391

Previous 1,993 120.32%

Holding current value

$13,173

Previous $6,000 133.33%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 25, 2024	BUY	$2.31 - $4.99 $5,539 - $11,966	2,398 Added 120.32%	4,391 $14,000
Q1 2024 Apr 25, 2024	BUY	$2.94 - $4.34 $5,859 - $8,649	1,993 New	1,993 $6,000
Q3 2023 Nov 01, 2023	SELL	$6.5 - $10.77 $48,269 - $79,978	-7,426 Reduced 39.89%	11,192 $76,000
Q2 2023 Aug 04, 2023	BUY	$6.69 - $12.25 $90,602 - $165,901	13,543 Added 266.86%	18,618 $193,000
Q1 2023 Apr 27, 2023	SELL	$6.38 - $12.5 $94,723 - $185,587	-14,847 Reduced 74.53%	5,075 $35,000
Q4 2022 Feb 02, 2023	BUY	$5.75 - $8.5 $114,551 - $169,337	19,922 New	19,922 $120,000
Q2 2022 Aug 03, 2022	SELL	$13.18 - $19.41 $263,230 - $387,656	-19,972 Closed	0 $0
Q1 2022 May 02, 2022	BUY	$14.73 - $35.25 $162,619 - $389,160	11,040 Added 123.6%	19,972 $391,000
Q4 2021 Feb 23, 2022	BUY	$33.72 - $48.22 $278,729 - $398,586	8,266 Added 1241.14%	8,932 $306,000
Q3 2021 Oct 28, 2021	BUY	$49.26 - $74.5 $32,807 - $49,617	666 New	666 $45,000
Q1 2021 Apr 26, 2021	SELL	$79.79 - $126.29 $14,441 - $22,858	-181 Closed	0 $0
Q4 2020 Feb 02, 2021	BUY	$46.76 - $136.27 $8,463 - $24,664	181 New	181 $0

Others Institutions Holding CVAC

# of Institutions

Shares Held

14.4M

Call Options Held

241K

Put Options Held

419K

View Full List

About CureVac N.V.

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $562M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

More about CVAC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.

Account

Simplex Trading, LLC Cure Vac N.V. Transaction History